LEP and breast carcinoma: Breast cancer cells overexpressing miR-205 reduced leptin-mediated Med1, TFF1, and CATD overexpression whereas expression of miR-205-inhibitor potentiated the effect of leptin on Med1 expression (Fig. 3M).